" class="no-js "lang="en-US"> BCI Pharma - Medtech Alert
Tuesday, September 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
BCI Pharma | Pharmtech Focus

BCI Pharma

About BCI Pharma

BCI Pharma

BCI Pharma is an innovative bio-pharmaceutical company focused on small molecule drug discovery. We design innovative chemical libraries and our HTS platform can support your owned library synthesis.

Founded by :
– Dr. Dominique Surleraux who was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec).
– Dr. Elisabeth Picou who had a position in a hospital, treating patients with infectious diseases.

Related Story

Diseases

 BCI Pharma Enters into Strategic Partnership with Mithra to Identify Novel Therapy for Endometriosis and Cancer in Women | Pharmtech Focus

BCI Pharma Enters into Strategic Partnership with Mithra to Identify Novel Therapy for Endometriosis and Cancer in Women

December 16 2021

BCI Pharma, owner of a proprietary kinase technology platform, and Mithra, a global independent pharmaceutical group, today announce […]